The Food and Drug Administration (FDA) has issued an advisory regarding the Guidelines on the Re-issuance of Order of Payment following the temporary suspension of AO No. 2024-0016. Applications filed during the effectivity of the said AO but not yet paid may request a reissued Order of Payment reflecting the previous (lower) fees.
Applications filed during the effectivity of AO No. 2024-0016 but with no payment made may request the reissuance of the Order of Payment by sending an email message to the respective centers.
Requests must be sent to the appropriate FDA Center via email, attaching the original Order of Payment. For multiple applications, each request must be submitted in a separate email.
Refer to the advisory for complete instructions and contact details:
FDA Advisory No.2025 0729 [PDF]
Effectivity
- FDA has released guidelines on reissuing Orders of Payment following the suspension of AO No. 2024-0016.
- Applications filed under AO No. 2024-0016 but not yet paid may request reissuance reflecting previous (lower) fees.
- Requests must be submitted via email to the appropriate FDA Center, with the original Order of Payment attached, and each request sent in a separate email for multiple applications.
Implications to Clients
Clients who have submitted applications but have not yet paid under AO No. 2024-0016 may still qualify for the lower fees based on A.O. 50 s. 2001. This provides a cost-saving opportunity for pending transactions, provided that a request for reissuance of the Order of Payment is submitted in accordance with FDA guidelines.
For more information or assistance, contact us at sales@andamanmed.com or click the button below.
